Logo image of 9VC.DE

ATAI LIFE SCIENCES NV (9VC.DE) Stock Fundamental Analysis

FRA:9VC - NL0015000DX5 - Common Stock

3.837 EUR
+0.13 (+3.45%)
Last: 9/5/2025, 7:00:00 PM
Fundamental Rating

3

Taking everything into account, 9VC scores 3 out of 10 in our fundamental rating. 9VC was compared to 50 industry peers in the Pharmaceuticals industry. 9VC has a great financial health rating, but its profitability evaluates not so good. 9VC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year 9VC has reported negative net income.
9VC had a negative operating cash flow in the past year.
9VC had negative earnings in each of the past 5 years.
9VC had a negative operating cash flow in each of the past 5 years.
9VC.DE Yearly Net Income VS EBIT VS OCF VS FCF9VC.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

9VC has a worse Return On Assets (-78.89%) than 86.00% of its industry peers.
9VC's Return On Equity of -103.85% is on the low side compared to the rest of the industry. 9VC is outperformed by 80.00% of its industry peers.
Industry RankSector Rank
ROA -78.89%
ROE -103.85%
ROIC N/A
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
9VC.DE Yearly ROA, ROE, ROIC9VC.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for 9VC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
9VC.DE Yearly Profit, Operating, Gross Margins9VC.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

8

2. Health

2.1 Basic Checks

9VC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 9VC has been increased compared to 1 year ago.
9VC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for 9VC is higher compared to a year ago.
9VC.DE Yearly Shares Outstanding9VC.DE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
9VC.DE Yearly Total Debt VS Total Assets9VC.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

9VC has an Altman-Z score of 5.86. This indicates that 9VC is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5.86, 9VC belongs to the best of the industry, outperforming 82.00% of the companies in the same industry.
9VC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.86
ROIC/WACCN/A
WACC7.4%
9VC.DE Yearly LT Debt VS Equity VS FCF9VC.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 4.02 indicates that 9VC has no problem at all paying its short term obligations.
With an excellent Current ratio value of 4.02, 9VC belongs to the best of the industry, outperforming 92.00% of the companies in the same industry.
A Quick Ratio of 4.02 indicates that 9VC has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 4.02, 9VC belongs to the best of the industry, outperforming 94.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 4.02
9VC.DE Yearly Current Assets VS Current Liabilites9VC.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

9VC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -72.50%.
9VC shows a decrease in Revenue. In the last year, the revenue decreased by -1.91%.
The Revenue for 9VC have been decreasing by -75.28% on average. This is quite bad
EPS 1Y (TTM)-72.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.11%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%163.37%

3.2 Future

Based on estimates for the next years, 9VC will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.45% on average per year.
Based on estimates for the next years, 9VC will show a very strong growth in Revenue. The Revenue will grow by 238.35% on average per year.
EPS Next Y48.51%
EPS Next 2Y23.19%
EPS Next 3Y13.79%
EPS Next 5Y13.45%
Revenue Next Year314.74%
Revenue Next 2Y-41.84%
Revenue Next 3Y332.61%
Revenue Next 5Y238.35%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
9VC.DE Yearly Revenue VS Estimates9VC.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
9VC.DE Yearly EPS VS Estimates9VC.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

9VC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 9VC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
9VC.DE Price Earnings VS Forward Price Earnings9VC.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
9VC.DE Per share data9VC.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

9VC's earnings are expected to grow with 13.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.19%
EPS Next 3Y13.79%

More info and screens

0

5. Dividend

5.1 Amount

9VC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATAI LIFE SCIENCES NV

FRA:9VC (9/5/2025, 7:00:00 PM)

3.837

+0.13 (+3.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners9.44%
Inst Owner ChangeN/A
Ins Owners2.69%
Ins Owner ChangeN/A
Market Cap822.42M
Analysts84
Price Target9.79 (155.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.25%
Min EPS beat(2)-17.64%
Max EPS beat(2)17.15%
EPS beat(4)1
Avg EPS beat(4)-15.72%
Min EPS beat(4)-62.27%
Max EPS beat(4)17.15%
EPS beat(8)4
Avg EPS beat(8)10%
EPS beat(12)7
Avg EPS beat(12)5.89%
EPS beat(16)9
Avg EPS beat(16)-5.32%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)28.3%
PT rev (3m)38.79%
EPS NQ rev (1m)-4.5%
EPS NQ rev (3m)30.7%
EPS NY rev (1m)1.17%
EPS NY rev (3m)30.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)45.56%
Revenue NY rev (3m)16.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3123.34
P/FCF N/A
P/OCF N/A
P/B 6.69
P/tB 6.86
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0
BVpS0.57
TBVpS0.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.89%
ROE -103.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 830.23%
Cap/Sales 2024.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.02
Quick Ratio 4.02
Altman-Z 5.86
F-Score2
WACC7.4%
ROIC/WACCN/A
Cap/Depr(3y)268.35%
Cap/Depr(5y)673.01%
Cap/Sales(3y)220.74%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.11%
EPS Next Y48.51%
EPS Next 2Y23.19%
EPS Next 3Y13.79%
EPS Next 5Y13.45%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%163.37%
Revenue Next Year314.74%
Revenue Next 2Y-41.84%
Revenue Next 3Y332.61%
Revenue Next 5Y238.35%
EBIT growth 1Y18.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.41%
EBIT Next 3Y-15.65%
EBIT Next 5Y-3.12%
FCF growth 1Y21.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.11%
OCF growth 3YN/A
OCF growth 5YN/A